Aduro's staffers feel the sting, again, after Novartis walks away

It’s grim news ahead of the J.P. Morgan Healthcare Conference next week for Aduro Biotech.

The company, which is working on so-called STING and APRIL pathways to try to halt cancer, autoimmune and inflammatory diseases, already cut more than a third of its staffers 12 months back, with that coming off the back of some weak trial results.

Now, it’s cutting a further 59% of its workforce as well as axing its headquarters, known as Aduro Biotech Europe, in Oss, Netherlands, by the end of the third quarter.